 Adagene Inc NASDAQ: ADAG has entered into a third clinical trial collaboration and supply agreement with Merck Co Inc NYSE: MRK. The agreement includes an open-label, dose-escalation, and expansion clinical study of ADG106 combined with Mercks Keytruda pembrolizumab in advanced or metastatic solid andor hematological malignancies. 